Saniona (SANION) Q2 2025 earnings summary

Executive summary

• Achieved two major partnerships within a year, including a transformative licensing deal with Jazz Pharmaceuticals for SAN2355 in epilepsy, securing a $42.5M upfront payment and potential milestones up to $992.5M.

• Strengthened financial position through TO4 warrant exercise (SEK 111.3M), Jazz and Acadia deals, and acquisition of headquarters for long-term stability.

• Internal pipeline advanced, with SAN2219 and SAN2465 progressing toward Phase 1, and Tesofensine regulatory review ongoing in Mexico.

Financial highlights

• Q2 2025 revenue was SEK 9.3M (up from SEK 8.0M YoY); H1 2025 revenue SEK 19.1M (up from SEK 14.1M YoY).

• Q2 operating loss widened to SEK -25.9M (from SEK -16.0M YoY); H1 operating loss SEK -42.4M (from SEK -29.7M YoY).

• H1 net loss narrowed to SEK -3.3M (from SEK -29.0M YoY), aided by a SEK 33.6M fair value gain on TO4 warrants.

• Cash and cash equivalents at period end: SEK 308.2M (up from SEK 54.4M YoY).

• Equity ratio improved to 84% (from 7% YoY); equity at SEK 356.3M.

Outlook and guidance

• Focused on advancing internal pipeline (SAN2219, SAN2465, AN2668) into Phase 1/2 trials over the next 2–3 years, funded by recent deals.

• Jazz and Acadia partnerships provide non-dilutive capital and validate R&D approach; further partnerships may be pursued.